EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival Trends and Prognostic Modeling in ALK ‐Positive Anaplastic Large Cell Lymphoma: A Population‐Based Study in the Brentuximab Vedotin Era

Qiuyu Zhang, Yanyan Liu

Cancer Medicine · 2026-03 · 15 (3)

DOI: 10.1002/cam4.71695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 06.03.2026. Verfasst von Qiuyu Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Lymphoma, Large-Cell, Anaplastic, Anaplastic Lymphoma Kinase, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ALK‐positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare subtype of peripheral T‐cell lymphoma with traditionally favorable prognosis. The introduction of brentuximab vedotin (BV) has significantly impacted treatment outcomes, but the long‐term survival trends and predictive factors for this population remain underexplored.

Methods

A total of 1548 patients diagnosed with ALK+ ALCL between 2004 and 2017 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were categorized into two eras: pre–BV (2004–2010, n = 795) and post–BV (2011–2017, n = 753). Overall survival (OS) was compared between eras. A random survival forest (RSF) model was constructed to identify prognostic factors and stratify survival risk in the post–BV cohort.

Results

OS significantly improved in the post–BV era (HR = 0.68, 95% CI: 0.58–0.81, p < 0.001), with the 5‐year OS increasing from 59.3% to 72.3%. The RSF model identified age, Ann Arbor stage, primary site, B symptoms, and radiotherapy as key prognostic factors, showing good discrimination with C‐indices of 0.775 (training cohort) and 0.728 (testing cohort). Notably, radiotherapy was found to be a protective factor. The model effectively stratified patients into high‐risk (5‐year OS: 49.3%) and low‐risk (86.0%) groups.

Conclusion

The introduction of BV has significantly improved real‐world survival in ALK+ ALCL. The RSF model enables individualized risk stratification and may support future precision treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brentuximab VedotinLymphoma, Large-Cell, AnaplasticAnaplastic Lymphoma KinaseAntineoplastic Agents, ImmunologicalHumansFemalePrognosisMiddle AgedMaleSEER ProgramAgedAdultYoung AdultRandom Forest

Stichwörter der Autor:innen

ALK‐positive anaplastic large cell lymphomaSEER databasebrentuximab vedotinmachine learningrandom survival forest

Substanzen

Brentuximab VedotinAnaplastic Lymphoma KinaseALK protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Q., & Liu, Y. (2026). Survival Trends and Prognostic Modeling in ALK ‐Positive Anaplastic Large Cell Lymphoma: A Population‐Based Study in the Brentuximab Vedotin Era. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71695

Vancouver

Zhang Q, Liu Y. Survival Trends and Prognostic Modeling in ALK ‐Positive Anaplastic Large Cell Lymphoma: A Population‐Based Study in the Brentuximab Vedotin Era. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71695

BibTeX
@article{Zhang2026,
  author = {Zhang, Qiuyu and Liu, Yanyan},
  title = {Survival Trends and Prognostic Modeling in ALK ‐Positive Anaplastic Large Cell Lymphoma: A Population‐Based Study in the Brentuximab Vedotin Era},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cam4.71695}
}
Kostenlos starten →